C. Malerczyk

发表

Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.

G. Wensing, K. Breithaupt-Grögler, C. Malerczyk, 1997, International journal of clinical pharmacology and therapeutics.

Emergence of Neisseria meningitidis W-135 in the context of other rare serogroups

Z. Memish, L. DeTora, C. Malerczyk, 2012 .

Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine.

C. Malerczyk, J. Beran, A. Banzhoff, 2005, Vaccine.

Ramipril in angina pectoris: short-term effects on glucose, insulin, C-peptide, adrenocorticotropic hormone, and cortisol levels

K. Usadel, B. Winkelmann, T. Haak, 1996 .

Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species

T. Selhorst, C. Malerczyk, D. Gniel, 2014, Human vaccines & immunotherapeutics.

Rabies Pre-Exposure Vaccination in Rabies Endemic Countries

C. Malerczyk, 2012 .

Neurohumoral effects of ramipril in angina pectoris: A double-blind, placebo-controlled trial against isosorbide dinitrate and the combination of ramipril plus isosorbide dinitrate

B. Winkelmann, C. Malerczyk, G. Grönefeld, 1994 .

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.

A. Aigner, F. Czubayko, C. Malerczyk, 2000, Toxicology.

Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.

S. Magin, C. Malerczyk, G. Belz, 1997, Journal of human hypertension.

Invasive meningococcal disease and travel.

Z. Memish, C. Malerczyk, A. Shibl, 2010, Journal of infection and public health.

Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine.

C. Malerczyk, A. Banzhoff, D. Briggs, 2007, Journal of travel medicine.

Imported human rabies cases in europe, the United States, and Japan, 1990 to 2010.

L. DeTora, C. Malerczyk, D. Gniel, 2011, Journal of travel medicine.

Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study

C. Malerczyk, A. Arora, A. Banzhoff, 2017, Human vaccines & immunotherapeutics.

30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience

C. Malerczyk, D. Gniel, A. Giesen, 2015, Expert review of vaccines.

Protecting Indian schoolchildren against rabies: Pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV)

M. Kulkarni, C. Malerczyk, N. Shah, 2008, Human vaccines.

Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*

D. Wen, I. Sunitha, A. Wellstein, 2001, The Journal of Biological Chemistry.

Ribozyme Targeting of Angiogenic Molecules

A. Wellstein, A. Riegel, A. Aigner, 1999 .

Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach

A. Wellstein, F. Czubayko, L. Bellon, 2005, Gene Therapy.

Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.

C. Malerczyk, A. Laiskonis, A. Ambrozaitis, 2006, Vaccine.

Correction to: 30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience.

C. Malerczyk, D. Gniel, A. Giesen, 2015, Expert review of vaccines.

ERbB‐2 expression is rate‐limiting for epidermal growth factor–mediated stimulation of ovarian cancer cell proliferation

A. Aigner, F. Czubayko, C. Malerczyk, 2000, International journal of cancer.

A Three-Year Clinical Study On Immunogenicity, Safety, and Booster Response of Purified Chick Embryo Cell Rabies Vaccine Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children, Concomitantly With Japanese Encephalitis Vaccine

K. Pengsaa, C. Malerczyk, A. Sabchareon, 2009, The Pediatric infectious disease journal.

Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe.

C. Malerczyk, A. Banzhoff, P. Khawplod, 2007, The Journal of pediatrics.

Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals.

B. Quiambao, C. Malerczyk, E. Dimaano, 2005, Vaccine.

Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains.

T. Selhorst, N. Tordo, C. Malerczyk, 2009, Vaccine.

Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV)

C. Malerczyk, W. Bender, H. Vakil, 2013, Human vaccines & immunotherapeutics.

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren

G. Anders, C. Malerczyk, P. Khawplod, 2011, Advances in preventive medicine.

Human rabies, a disease of the poor — also in travelers?

C. Malerczyk, 2013, Pathogens and global health.

Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus.

C. Malerczyk, S. Manatsathit, Sanit Kumperasart, 2009, Vaccine.

Purified Chick-Embryo Cell Vaccine

C. Malerczyk, Helmut Muller, 2015 .

How far can the antigen content of tissue culture rabies vaccine be reduced safely?

C. Malerczyk, J. Beran, A. Banzhoff, 2006, Vaccine.

Ticks on the turf: investigating the presence of ixodid ticks on and around football fields in Germany

C. Malerczyk, C. von Eiff, O. Kahl, 2021, Experimental and Applied Acarology.

Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany.

J. Süss, C. Malerczyk, C. von Eiff, 2021, Vaccine.

Evaluation of under-testing and under-diagnosis of tick-borne encephalitis in Germany

C. Malerczyk, Andreas Pilz, Liping Huang, 2023, BMC Infectious Diseases.

The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes

A. Aigner, F. Czubayko, C. Malerczyk, 2001, Oncogene.

Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site

A. Wellstein, A. Riegel, C. Malerczyk, 2000, Oncogene.

Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation

C. Benz, H. Juhl, A. Aigner, 2001, Oncogene.

Monitoring daunorubicin‐induced alterations in protein expression in pancreas carcinoma cells by two‐dimensional gel electrophoresis

U. Völker, C. Malerczyk, E. Maser, 2002, Proteomics.

Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man

K. Breithaupt-Grögler, C. Malerczyk, G. Belz, 2000, The Journal of pharmacy and pharmacology.

Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data.

C. Malerczyk, C. Hagemann, T. Wilke, 2022, Vaccine.

1353. Incidence of Lyme Borreliosis in Germany: Exploring Observed Trends Over Time Using Public Surveillance Data, 2016–2020.

G. Brestrich, B. Gessner, C. Malerczyk, 2022, Vector borne and zoonotic diseases.

Tissue Distribution and Retinoid-Mediated Downregulation of an FGF-Binding Protein FGF-BP) in the Rat

A. Wellstein, A. Aigner, C. Malerczyk, 2000, Growth factors.